Format

Send to

Choose Destination
Aliment Pharmacol Ther. 2004 Feb 1;19(3):295-301.

Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine.

Author information

1
IInd Department of Internal Medicine, Johann Wolfgang Goethe-University, Frankfurt, Germany. o.schroeder@em.uni-frankfurt.de

Abstract

BACKGROUND:

Crohn's disease is complicated by fistulas in 20-40% of patients at some time during the course of their illness. Azathioprine has been reported to heal fistulas in 30-40% of cases. Long-lasting effects by the anti-tumour necrosis factor-alpha antibody infliximab most often require repeated infusions. Methotrexate has been shown to be an effective drug in maintaining remission in Crohn's disease.

AIM:

To evaluate the combination of infliximab and methotrexate as therapy for fistulas in patients with Crohn's disease.

METHODS:

Twelve consecutive patients (mean age, 29.5 years) with fistulizing Crohn's disease resistant or intolerant to azathioprine were followed prospectively. Patients received three infusions of infliximab (5 mg/kg) and long-term methotrexate (20 mg/week). Therapy success was defined as sustained closure of fistulas > or = 6 months after fistula closure.

RESULTS:

In four of the 12 patients, complete closure of fistulas that persisted for > or = 6 months (median follow-up, 13.25 months) was observed. In three further patients, a partial response was noted. In five patients, persistent therapy success could not be achieved or therapy had to be stopped due to side-effects.

CONCLUSIONS:

A combination of infliximab with long-term methotrexate may be a promising concept in fistulizing Crohn's disease. Our data indicate the need for larger controlled trials.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center